Pharmacologic treatment of generalized anxiety disorder

Psychiatric Clinics of North America

Volumn 24, Issue 1, 2001, Pages 119-137

  Brawman Mintzer, Olga ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE; BUSPIRONE; CHLORDIAZEPOXIDE; CLOMIPRAMINE; DELORAZEPAM; DIAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; FLUVOXAMINE; GEPIRONE; HYDROXYZINE; IMIPRAMINE; IPSAPIRONE; LORAZEPAM; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PRAZEPAM; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANXIETY NEUROSIS; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; REVIEW; SEXUAL DYSFUNCTION; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 0035129506     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(05)70209-4     Document Type: Article

References (87)

1. Comorbidity of anxiety, phobia, compulsion and depression
2. Paroxetine treatment of GAD: A double-blind, placebo-controlled trial
3. A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting
4. Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients
5. Generalized anxiety disorder: Issues in epidemiology
6. Somatic symptoms in generalized anxiety disorder with or without comorbid psychiatric disorders
7. Psychiatric comorbidity in patients with generalized anxiety disorder
8. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders
9. The empirical basis of generalized anxiety disorder
10. Serotonergic studies in patients with affective and personality disorders
11. Long-term comparison of alprazolam, lorazepam, and placebo in patients with an anxiety disorder
12. A phase II multicenter dose-finding, efficacy, and safety trial of ipsapirone in outpatients with generalized anxiety disorder
13. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: A prospective multicenter trial
14. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder
15. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting buspirone from prior treatment with lorazepam: A placebo-controlled, double-blind study
16. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder
17. Alprazolam and diazepam in the treatment of generalized anxiety
18. A case series study of the role of sertraline in the treatment of generalized anxiety disorder
19. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder
20. Response of anxiety and agitation symptoms during nefazodone treatment of major depression
21. Recent clinical trials of hydroxyzine in generalized anxiety disorder
22. Comparison of withdrawal of buspirone and diazepam: A placebo-controlled study
23. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms: A meta-analysis of eight randomized, controlled studies
24. The comparative efficacy of buspirone and diazepam in the treatment of anxiety
25. Mirtazapine in major depression with comorbid generalized anxiety disorder
26. An open trial of fluoxetine in the treatment of panic attacks
27. An open trial of nefazodone in adult patients with generalized anxiety disorder
28. Management of sexual side effects of antidepressant therapy
29. Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms
30. The assessment and treatment of refractory anxiety
31. Anxious and nonanxious depression
32. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: Vulnerability and effect of carbamazepine
33. The relationship between anxiety disorders and alcohol use disorders: A review of major perspectives and findings
34. SSRI-induced extrapyramidal side effects and akathisia: Implications for treatment
35. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients
36. Limitations on the use of benzodiazepines in anxiety and insomnia: Are they justified?
37. A multicentre double-blind comparison of hydroxyzine, buspirone, and placebo in patients with generalized anxiety disorder
38. A multicenter double-blind comparative trial of fluvoxamine versus lorazepam in anxiety and depression treated in general practice
39. Alcohol and depression in panic disorder
40. Recent developments in the psychopharmacology of anxiety disorders
41. Long-term follow-up of generalized anxiety disorder
42. Evaluation of the ratings comprising the associated symptom criterion of DSM-III-R generalized anxiety disorder
43. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder
44. The impact of comorbid mood and personality disorders in the cognitive-behavioral treatment of panic disorder
45. Female sexual dysfunction associated with antidepressant administration: A randomized, placebo-controlled study of pharmacologic intervention
46. Diagnosis and outcome: Depression and anxiety in a general population
47. The prognosis of anxiety neuroses
48. Treating anxiety in patients with alcoholism
49. Management of patients with depression associated with anxiety symptoms
50. A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states
51. Common mental disorders and disability across cultures: Results from the WHO collaborative study on psychological problems in general health care
52. Buspirone: Anxiolytic?
53. Evaluation of buspirone as an antianxiety agent: Buspirone and diazepam versus placebo
54. Gabapentin as a potential treatment for anxiety disorders
55. Abecarnil for the treatment of generalized anxiety disorder: A placebo-controlled comparison of two dosage ranges of abecarnil and buspirone
56. Long-term buspirone therapy for chronic anxiety: A multicenter international study to determine safety
57. Effect of personality disorders on the treatment outcome of Axis l conditions: An update
58. Comorbidity of affective and anxiety disorders in the NIMH epidemiologic catchment area program
59. One-year follow-up of anxious patients treated with diazepam
60. Relapse after short-term drug therapy in neurotic outpatients
61. A controlled clinical trial of alprazolam for the treatment of anxiety
62. Antidepressants for the treatment of generalized anxiety disorder
63. The clinical course and long-term management of generalized anxiety disorder
64. The treatment of generalized anxiety disorder in patients with depressive symptomatology
65. Long-term treatment of anxiety and risk of withdrawal
66. Gepitone and diazepam in goneralized anxiety disorder: A placebo-controlled trial
67. Buspirone and diazepam in anxiety: A controlled study
68. Alprazolam and oxazepam in the treatment of anxious outpatients with depressive symptoms: A double-blind multicenter study
69. Paroxetine efficacy in the treatment of generalized anxiety disorder
70. Clinical aspects of chronic use of alprazolam and lorazepam
71. Effects of SSRIs on sexual function: A critical review
72. A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder
73. A double-blind study of alprazolam and lorazepam in the treatment of anxiety
74. The impact of clinically diagnosed personality disorders on acute and one-year outcomes of electroconvulsive therapy
75. Depression comorbid with anxiety: Results from the WHO study on psychological disorders in primary health care
76. Resistance to the anxiety effect of buspirone in patients with a history of benzodiazepine use
77. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder
78. The effect of paroxetine on anxiety and agitation associated with depression
79. Ravindran A for the Veniafaxine XR 360: Once-daily venlafaxine extended release (XR) compared with fiuoxetine in outpatients with depression and anxiety
80. Cost of anxiety disorders: Impact of comorbidity
81. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms
82. International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992- 1997
83. Buspirone: Multicenter efficacy study
84. Clomipramine treatment for generalized anxiety disorder
85. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey
86. A 5-year follow-up study of generalized anxiety disorder and panic disorder
87. Phenomenology and course of generalized anxiety disorder